<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416999</url>
  </required_header>
  <id_info>
    <org_study_id>YDCR-2015-001</org_study_id>
    <nct_id>NCT02416999</nct_id>
  </id_info>
  <brief_title>Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas</brief_title>
  <official_title>Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Yanda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Yanda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide
      for recurrent high-grade gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus
      Temozolomide for recurrent high-grade gliomas. And, this trial is approved by medical ethics
      committee of Hebei Yanda Hospital.Researchers will conduct thsi trial from 2015/05 to
      2018/05, and 30 recurrent high-grade glioma patients will be recruited. Patients who are
      recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei
      Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month survival rate of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-month survival rate of recurrent WHO-III glioma patients under ultra-low dose Bevacizumab plus Temozolomide treatment</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment</measure>
    <time_frame>6 months or later, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of recurrent WHO-III glioma patients under ultra-low dose Bevacizumab plus Temozolomide treatment</measure>
    <time_frame>12 months or later, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival of recurrent glioblastoma multiforme patients under ultra-low dose Bevacizumab plus Temozolomide treatment</measure>
    <time_frame>6 months or later, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival of recurrent WHO-III glioma patients under ultra-low dose Bevacizumab plus Temozolomide treatment</measure>
    <time_frame>12 months or later, up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month life quality as measured by European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30 and EORTC QLQ-BN20 together)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month life quality as measured by European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30 and EORTC QLQ-BN20 together)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Recurrent High-grade Glioma</condition>
  <arm_group>
    <arm_group_label>patient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultra-low dose Bevacizumab</intervention_name>
    <arm_group_label>patient group</arm_group_label>
    <other_name>BVZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>patient group</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High grade glioma was diagnosed by post-operation pathological method, and shows a
             relapse.

          -  Before included, the patient needs imageological examinations, and the diameter of
             contrast enhancing area is bigger than 1cm, PET or MRS results show positive features.

          -  The age of patient should be between 18 years old and 70 years old.

          -  The condition of the patient permits the treatment of ultra-low dose Bevacizumab plus
             Temozolomide.

          -  The patient is informed consent,and willing to join in this research.

        Exclusion Criteria:

          -  The diagnosis is not recurrent high-grade glioma.

          -  The diagnosis of high-grade glioma was not established by pathological method.

          -  The results of imageological examinations do not meet the standard of including.

          -  The age of the patient does not meet the requirement of this research.

          -  The condition of the patient does not permit the treatment of ultra-low dose
             Bevacizumab plus Temozolomide.

          -  There are other conditions that the clinicians believe that the treatment of ultra-low
             dose Bevacizumab plus Temozolomide is not appropriate for the patient.

          -  The patient is not willing to join in this research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jisheng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nan Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nan Ji, MD</last_name>
    <phone>+86 13910713896</phone>
    <email>neurochina@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jisheng Wang, MD</last_name>
    <phone>+86 15210503095</phone>
    <email>neurowang@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nan Ji, MD</last_name>
      <phone>+86 13910713896</phone>
      <email>neurochina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jisheng Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nan Ji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Yanda Hospital</name>
      <address>
        <city>Sanhe</city>
        <state>Hebei</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nan Ji, MD</last_name>
      <phone>+86 13910713896</phone>
      <email>neurochina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jisheng Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nan Ji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>high-grade glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

